title: Regulation of inflammatory responses by oncostatin M.
abstract: Oncostatin M (OM) is a pleiotropic cytokine produced late in the activation cycle of T cells and macrophages. In vitro it shares properties with related proteins of the IL-6 family of cytokines; however, its in vivo properties and physiological function are as yet ill defined. We show that administration of OM inhibited bacterial LPS-induced production of TNF-alpha and lethality in a dose-dependent manner. Consistent with these findings, OM potently suppressed inflammation and tissue destruction in murine models of rheumatoid arthritis and multiple sclerosis. T cell function and Ab production were not impaired by OM treatment. Taken together these data indicate the activities of this cytokine in vivo are antiinflammatory without concordant immunosuppression.
authors.affiliation: Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, WA 98121, USA. philipvwallace@msn.com
authors.forename: P M
authors.initials: PM
authors.lastname: Wallace
authors.forename: J F
authors.initials: JF
authors.lastname: MacMaster
authors.forename: K A
authors.initials: KA
authors.lastname: Rouleau
authors.forename: T J
authors.initials: TJ
authors.lastname: Brown
authors.forename: J K
authors.initials: JK
authors.lastname: Loy
authors.forename: K L
authors.initials: KL
authors.lastname: Donaldson
authors.forename: A F
authors.initials: AF
authors.lastname: Wahl
mesh_terms: D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D016207:Cytokines / Q000008:administration & dosage / Q000096:biosynthesis / Q000502:physiology*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology / Q000473:pathology / Q000517:prevention & control; D005260:Female; D006614:Hindlimb; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology; D018836:Inflammation Mediators / Q000008:administration & dosage / Q000378:metabolism / Q000502:physiology*; D007275:Injections, Intravenous; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008213:Lymphocyte Activation / Q000276:immunology; D008262:Macrophage Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D053683:Oncostatin M; D010455:Peptides / Q000008:administration & dosage / Q000378:metabolism / Q000502:physiology*
chemical_list: D016207:Cytokines; D007166:Immunosuppressive Agents; D018836:Inflammation Mediators; D008070:Lipopolysaccharides; C508351:OSM protein, human; C508352:Osm protein, mouse; D010455:Peptides; D053683:Oncostatin M